However, iPS-ML/anti-HER2/IFN-α and iPS-ML/anti-HER2/TRAIL exhibited no effect on the growth of peritoneally implanted NUGC-4 gastric cancer in vivo. Here, IFNA1 is linked to gastric cancer.